Bolt Biotherapeutics (BOLT) closed at $5.65 on November 17, 2026, down 2.6% from the previous close, on volume of 84,813 shares (30-day average 502,990).
Data as of November 17, 2026.
Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
PRNewswire (Tue, 3-Nov 12:19 PM ET)
Bolt Biotherapeutics to Participate in Upcoming Conferences
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
Market Chameleon (Mon, 26-Oct 7:22 AM ET)
PRNewswire (Mon, 26-Oct 10:15 AM ET)
Market Chameleon (Fri, 23-Oct 6:25 AM ET)
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Bolt Biotherapeutics trades on the NASDAQ stock market under the symbol BOLT.
As of November 17, 2026, BOLT stock price declined to $5.65 with 84,813 million shares trading.
BOLT has a beta of 0.05, meaning it tends to be less sensitive to market movements. BOLT has a correlation of 0.00 to the broad based SPY ETF.
BOLT has a market cap of $14.73 million. This is considered a Sub-Micro Cap stock.
Last quarter Bolt Biotherapeutics reported $0 in Revenue and -$2.25 earnings per share. This fell short of revenue expectation by $-300,000 and exceeded earnings estimates by $1.18.
In the last 3 years, BOLT traded as high as $31.20 and as low as $3.10.
The top ETF exchange traded funds that BOLT belongs to (by Net Assets): VXF.
BOLT has outperformed the market in the last year with a return of +25.3%, while the SPY ETF gained +11.2%. In the last 3 month period, BOLT beat the market returning +76.6%, while SPY returned -5.0%. However, in the most recent 2 weeks BOLT has underperformed the stock market by returning -14.0%, while SPY returned -2.9%.
BOLT support price is $5.46 and resistance is $6.14 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BOLT shares will trade within this expected range on the day.